The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 18, 2017

Filed:

Jan. 06, 2016
Applicant:

Children's Hospital Medical Center, Cincinnati, OH (US);

Inventors:

Marc E. Rothenberg, Cincinnati, OH (US);

Thomas Xuefeng Lu, Cincinnati, OH (US);

Assignee:

CHILDREN'S HOSPITAL MEDICAL CENTER, Cincinnati, OH (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12Q 1/68 (2006.01); C12N 15/11 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6883 (2013.01); C12N 15/111 (2013.01); C12N 2310/141 (2013.01); C12N 2320/10 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01);
Abstract

Methods and compositions disclosed herein generally relate to methods of treating eosinophilic esophagitis (EE) and eosinophilic disorders by providing or enhancing a diagnosis of EE and eosinophilic disorders. In particular, the invention relates to obtaining a sample from a patient, then quantifying from the sample an amount of one or more microRNAs (miRNAs) associated with EE, wherein an altered level of the miRNA correlates with a positive diagnosis of EE. An EE diagnosis can then be provided or enhanced, based upon the quantifying step, and an appropriate treatment can be administered to the patient. The invention further relates to diagnostic kits, tests, and/or arrays that can be used to quantify the one or more miRNAs associated with EE, as well as treatments developed to up-regulate or down-regulate one or more miRNAs and/or their downstream pathways relevant to EE or asthma. The invention further relates to the use of IGF1 and IGF1R inhibitors for the treatment of EE and eosinophilic disorders.


Find Patent Forward Citations

Loading…